Print

Liquidia Technologies Inc. Receives Significant Equity Investment to Bolster Development of Next Generation Vaccines  
3/4/2011 9:11:36 AM

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Liquidia Technologies today announced the Bill & Melinda Gates Foundation has made a $10 million program-related investment (PRI) in the company to support the development and commercialization of safer and more effective vaccines and therapeutics. This follows recent announcements of the first Liquidia clinical trial of its lead seasonal flu candidate (LIQ001) and a collaborative agreement with the PATH Malaria Vaccine Initiative (MVI).
//-->